journal
MENU ▼
Read by QxMD icon Read
search

ESMO Open

journal
https://www.readbyqxmd.com/read/30245864/preparing-for-the-incoming-wave-of-biosimilars-in-oncology
#1
Elena Wolff-Holz, Juan Garcia Burgos, Rosa Giuliani, Gustaf Befrits, Johan de Munter, Luisa Avedano, Murray Aitken, Rosa Gonzalez-Quevedo, Malvika Vyas, Elisabeth G E de Vries, Josep Tabernero
With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology's Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial...
2018: ESMO Open
https://www.readbyqxmd.com/read/30245863/alk-ihc-and-fish-discordant-results-in-patients-with-nsclc-and-treatment-response-for-discussion-of-the-question-to-treat-or-not-to-treat
#2
Florian Cabillic, Paul Hofman, Marius Ilie, Nir Peled, Maximilian Hochmair, Manfred Dietel, Maximilian Von Laffert, John R Gosney, Fernando Lopez-Rios, Gilles Erb, Uwe Schalles, Fabrice Barlesi
Introduction: Lung cancer is the most common cancer worldwide. Latest guidelines from the College of American Pathologist and the European society of medical oncologists indicate anaplastic lymphoma kinase (ALK) rearrangement testing is standard practice. Historically, diagnostics for ALK used fluorescence in situ hybridisation (FISH); however, immunohistochemical (IHC) assays are becoming common practice. Unfortunately, recent assessment of current practice indicated that not all patients who should be tested for ALK translocation are undergoing ALK testing...
2018: ESMO Open
https://www.readbyqxmd.com/read/30233824/cancer-and-the-arts-a-pacifist-s-guide-to-the-war-on-cancer
#3
Wolfgang Wagner
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/30233823/in-the-literature-august-2018
#4
Valentina Gambardella, Paloma Martin-Martorell, Andrés Cervantes
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/30233822/extra-cost-of-brain-metastases-bm-in-patients-with-non-squamous-non-small-cell-lung-cancer-nsclc-a-french-national-hospital-database-analysis
#5
Nicolas Girard, Delphine Cozzone, Lucie de Leotoing, Charlène Tournier, Alexandre Vainchtock, Bertrand Tehard, Alexis B Cortot
Purpose: To assess the incremental cost associated with the management of patients with primary non-squamous non-small cell lung cancer (NSCLC) with brain metastases at the time of diagnosis. Methods: Data were extracted from the French Hospital medical information database (Programme de Médicalisation des Systèmes d'Information (PMSI)). Patients with non-squamous NSCLC were identified through a diagnosis of lung cancer and a prescription of bevacizumab or pemetrexed...
2018: ESMO Open
https://www.readbyqxmd.com/read/30233821/somatic-cancer-genetics-in-the-uk-real-world-data-from-phase-i-of-the-cancer-research-uk-stratified-medicine-programme
#6
Colin R Lindsay, Emily C Shaw, Fiona Blackhall, Kevin G Blyth, James D Brenton, Anshuman Chaturvedi, Noel Clarke, Craig Dick, Thomas R J Evans, Geoff Hall, Andrew M Hanby, David J Harrison, Stephen R D Johnston, Malcolm D Mason, Dion Morton, Julia Newton-Bishop, Andrew G Nicholson, Karin A Oien, Sanjay Popat, Doris Rassl, Rowena Sharpe, Phillipe Taniere, Ian Walker, William A Wallace, Nicholas P West, Rachel Butler, David Gonzalez de Castro, Mike Griffiths, Peter W M Johnson
Introduction: Phase I of the Cancer Research UK Stratified Medicine Programme (SMP1) was designed to roll out molecular pathology testing nationwide at the point of cancer diagnosis, as well as facilitate an infrastructure where surplus cancer tissue could be used for research. It offered a non-trial setting to examine common UK cancer genetics in a real-world context. Methods: A total of 26 sites in England, Wales and Scotland, recruited samples from 7814 patients for genetic examination between 2011 and 2013...
2018: ESMO Open
https://www.readbyqxmd.com/read/30233820/predictive-value-of-improvement-in-the-immune-tumour-microenvironment-in-patients-with-breast-cancer-treated-with-neoadjuvant-chemotherapy
#7
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Koji Takada, Katsuyuki Takahashi, Takaharu Hatano, Tsutomu Takashima, Shuhei Tomita, Hisashi Motomura, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
Background: Tumour-infiltrating lymphocytes (TILs) can be used to monitor the immune tumour microenvironment (iTME) and predict treatment response and outcome in breast cancer. We evaluated the prognostic significance of the levels of CD8+ TILs and forkhead box protein (FOXP3)-positive TILs before and after neoadjuvant chemotherapy (NAC). Patients and methods: We examined 136 patients with breast cancer treated with NAC. The number of CD8+ TILs and FOXP3+ TILs in biopsy specimens and residual tumours was evaluated by immunohistochemistry...
2018: ESMO Open
https://www.readbyqxmd.com/read/30167332/rationale-and-design-of-the-trusty-study-a-randomised-multicentre-open-label-phase-ii-iii-study-of-trifluridine-tipiracil-plus-bevacizumab-versus-irinotecan-fluoropyrimidine-plus-bevacizumab-as-second-line-treatment-in-patients-with-metastatic-colorectal-cancer
#8
Takayuki Yoshino, Eiji Oki, Hiroaki Nozawa, Takako Eguchi-Nakajima, Hiroya Taniguchi, Satoshi Morita, Naruhito Takenaka, Daisuke Ozawa, Kuniaki Shirao
Background: Trifluridine/tipiracil is an oral agent approved for the treatment of patients with metastatic colorectal cancer (mCRC). Trifluridine is an antineoplastic thymidine analogue, and tipiracil improves its bioavailability. A phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with refractory mCRC demonstrated promising efficacy results with mild toxicity profile. It is important that quality of life be preserved in patients with mCRC without compromising their prognosis...
2018: ESMO Open
https://www.readbyqxmd.com/read/30167331/cdk4-6-inhibitors-in-the-treatment-of-patients-with-breast-cancer-summary-of-a-multidisciplinary-round-table-discussion
#9
REVIEW
Matthias Preusser, Leticia De Mattos-Arruda, Marc Thill, Carmen Criscitiello, Rupert Bartsch, Thomas Ruhstaller, Evandro de Azambuja, Christoph C Zielinski
This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be.
2018: ESMO Open
https://www.readbyqxmd.com/read/30116595/macrophage-repolarisation-therapy-in-colorectal-cancer
#10
Niels Halama
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/30116594/is-smoking-history-the-truly-best-biomarker-for-immune-checkpoint-inhibitor-treatment-in-advanced-non-small-cell-lung-cancer
#11
EDITORIAL
https://www.readbyqxmd.com/read/30116593/epigenetic-biomarkers-in-cancer
#12
Gerda Egger
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/30116592/impact-of-abiraterone-acetate-plus-prednisone-or-enzalutamide-on-fatigue-and-cognition-in-patients-with-metastatic-castration-resistant-prostate-cancer-initial-results-from-the-observational-aquarius-study
#13
Antoine Thiery-Vuillemin, Mads Hvid Poulsen, Edouard Lagneau, Guillaume Ploussard, Alison Birtle, Louis-Marie Dourthe, Dominique Beal-Ardisson, Elias Pintus, Redas Trepiakas, Laurent Antoni, Martin Lukac, Suzy Van Sanden, Geneviève Pissart, Alison Reid
Introduction: Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are commonly prescribed for metastatic castration-resistant prostate cancer (mCRPC). Data comparing their effects on patient-reported outcomes (PROs) from routine clinical practice are limited. Methods: AQUARiUS (NCT02813408) is an ongoing, two-cohort, prospective, observational, non-randomised, multicentre, phase IV European study assessing the effects of AAP and ENZ on PROs in 211 patients with mCRPC over 12 months...
2018: ESMO Open
https://www.readbyqxmd.com/read/30094076/patient-reported-outcomes-in-a-phase-ii-study-of-alectinib
#14
EDITORIAL
Yuichiro Ohe
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/30094075/multidisciplinary-molecular-tumour-board-a-tool-to-improve-clinical-practice-and-selection-accrual-for-clinical-trials-in-patients-with-cancer
#15
Christian Rolfo, Paolo Manca, Roberto Salgado, Peter Van Dam, Amelie Dendooven, Andreia Machado Coelho, Jose Ferri Gandia, Annemie Rutten, Willem Lybaert, Joanna Vermeij, Thomas Gevaert, Christine Weyn, Anneke Lefebure, Sofie Metsu, Steven Van Laere, Marc Peeters, Patrick Pauwels
Background: The complexity of delivering precision medicine to oncology patients has led to the creation of molecular tumourboards (MTBs) for patient selection and assessment of treatment options. New technologies like the liquid biopsy are augmenting available therapeutic opportunities. This report aims to analyse the experience of our MTB in the implementation of personalised medicine in a cancer network. Materials and methods: Patients diagnosed with solid tumours progressing to standard treatments were referred to our Phase I unit...
2018: ESMO Open
https://www.readbyqxmd.com/read/30094074/phase-ii-study-assessing-the-benefit-of-cisplatin-re-introduction-stop-and-go-strategy-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-the-ifct-1102-bucil-study-a-better-use-of-cisplatin-in-lung-cancer
#16
Jaafar Bennouna, Fabrice Barlesi, Pascal Do, Patrick Dumont, Jacques Cadranel, Didier Debieuvre, Werner Hilgers, Olivier Molinier, Elisabeth Quoix, Judith Raimbourg, Alexandra Langlais, Franck Morin, Pierre-Jean Souquet
Introduction: This single-arm phase II trial aimed to evaluate a stop-and-go strategy with cisplatin-based chemotherapy and bevacizumab in advanced non-squamous non-small cell lung cancer (NSCLC). Methods: Patients were initially treated with three cycles of pemetrexed, cisplatin plus bevacizumab (sequence 1) followed by bevacizumab maintenance and after progression, re-introduction of three cycles of pemetrexed, cisplatin plus bevacizumab (sequence 2) and pemetrexed plus bevacizumab maintenance...
2018: ESMO Open
https://www.readbyqxmd.com/read/30094073/phase-i-open-label-study-of-pasireotide-in-patients-with-braf-wild-type-and-nras-wild-type-unresectable-and-or-metastatic-melanoma
#17
Reinhard Dummer, Olivier Michielin, Mirjam Chantal Nägeli, Simone M Goldinger, Federico Campigotto, Ulrike Kriemler-Krahn, Herbert Schmid, Alberto Pedroncelli, Sara Micaletto, Dirk Schadendorf
Introduction: Somatostatin analogues exert antitumour activity via direct and indirect mechanisms. The present study was designed to assess the safety and efficacy of pasireotide in patients with BRAF -wild type (WT) and NRAS -WT metastatic melanoma. Patients and methods: Patients with unresectable and/or metastatic melanoma or Merkel cell carcinoma were eligible. Pasireotide was administered at different doses for ≤8 weeks in dose-escalation phase, followed by long-acting pasireotide 80 mg or lower dose in case of toxicity in follow-up phase up to six additional months...
2018: ESMO Open
https://www.readbyqxmd.com/read/30094072/benefit-of-adjuvant-chemotherapy-based-on-lymph-node-involvement-for-oesophageal-cancer-following-trimodality-therapy
#18
Christopher Nevala-Plagemann, Samual Francis, Courtney Cavalieri, Randa Tao, Jonathan Whisenant, Robert Glasgow, Courtney Scaife, Shane Lloyd, Ignacio Garrido-Laguna
Background: Oesophageal cancer (OC) survival rates have improved since the widespread adoption of neoadjuvant chemoradiation therapy (NACRT) followed by oesophagectomy (trimodality therapy). Unfortunately, the overall prognosis for patients with locally advanced disease remains poor. In this study, we sought to assess the effect of adjuvant chemotherapy (AC) in patients treated with trimodality therapy. Methods: Using the National Cancer Database we retrospectively identified 6785 patients with locally advanced (cT1b-T4a, N0-N+, M0) OC who were treated with trimodality therapy from 2006 to 2014...
2018: ESMO Open
https://www.readbyqxmd.com/read/30094071/challenge-of-implementing-clinical-practice-guidelines-getting-esmo-s-guidelines-even-closer-to-the-bedside-introducing-the-esmo-practising-oncologists-checklists-and-knowledge-and-practice-questions
#19
EDITORIAL
Stefan Rauh, Dirk Arnold, Sofia Braga, Razvan Curca, Robert Eckert, Ana Fröbe, Michalis Karamouzis, Gabor Lakatos, Jean-Luc Molitor
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/30094070/association-of-homogeneous-inflamed-gene-signature-with-a-better-outcome-in-patients-with-metastatic-melanoma-treated-with-mage-a3-immunotherapeutic
#20
Jean-François Baurain, Caroline Robert, Laurent Mortier, Bart Neyns, Florent Grange, Céleste Lebbe, Fernando Ulloa-Montoya, Pedro Miguel De Sousa Alves, Marc Gillet, Jamila Louahed, Silvija Jarnjak, Frédéric F Lehmann
Purpose: This study assessed clinical activity, safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with MAGE-A3-positive metastatic melanoma. Patients and methods: In this open-label, multicentre, uncontrolled, Phase II study (ClinicalTrials.gov NCT00896480), patients received ≤24 doses of MAGE-A3 immunotherapeutic (4-cycle schedule). At screening, two skin lesions were biopsied for MAGE-A3 expression analysis and presence/absence of a previously identified gene signature (GS) associated with favourable clinical outcome...
2018: ESMO Open
journal
journal
53848
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"